New efficacy of LTRAs (montelukast sodium): it possibly prevents food-induced abdominal symptoms during oral immunotherapy

Masaya Takahashi, Shoichiro Taniuchi*, Kazuhiko Soejima, Kyoko Sudo, Yasuko Hatano and Kazunari Kaneko

Abstract

Background: The aim of the study was to elucidate whether leukotriene receptor antagonists (LTRAs) can prevent severe allergic reactions, which occur during oral immunotherapy (OIT) in children with food allergies.

Findings: Five children with food allergies [3 allergic to hen's egg (HE), 1 to wheat, and one to cow's milk (CM); aged between 7 and 12 years; median, 8.5 years] who were started on LTRAs during OIT were retrospectively selected from among 63 children undergoing OIT. In the rush phase, after the administration of the initial dose which was set in open food challenge test, the subsequent doses were increased by approximately 1.2 times of the previous dose and were administered every 2 hours, 4 times a day. The target doses of hen's egg, wheat (udon noodle), and cow's milk in the rush phase were 50 g, 200 g, and 200 ml, respectively. The ingestion of the target dose was continued at home every day for at least a year in the maintained phase.

Four participants experienced intractable abdominal pain during the rush phase; therefore, the loading dose was not increased in these children. However, the administration of LTRAs prevented their symptoms, resulting in the completion of the rush phase. One participant also experienced intractable abdominal pain during the maintenance phase. After receiving LTRAs, the target dose was able to tolerated.

Conclusion: The findings from this retrospective study suggest that the administration of LTRAs is useful for the prevention of adverse allergic reactions such as abdominal pain during OIT.

Keywords: Abdominal pain, Food allergy, LTRA (montelukast sodium), Rush oral immunotherapy

Findings

Food allergy is defined as an adverse response to a specific food antigen that is initiated by the immune system. The only current treatment for food allergy is avoidance, while maintaining the hope of outgrowing it over time. Although some trials of oral immunotherapy (OIT) in patients with food allergy have been carried out, the rate of tolerance induction remains uncertain, and food-induced allergic symptoms frequently occur [1].

Eosinophilic gastroenteritis (EG) has been strongly associated with food allergy, and concomitant atopic disease or a family history of allergy is elicited in about 70% of cases [2].

Leukotriene receptor antagonists (LTRAs) alleviate the symptoms of many allergic diseases, including respiratory symptoms such as bronchial asthma [3] and abdominal symptoms such as those occurring during EG [4].

During OIT, patients are sometimes not able to continue the therapy due to severe allergic symptoms, especially intractable abdominal pain, repeated vomiting, and diarrhea. Antihistamines and LTRAs have preventive effects in urticaria and wheezing, respectively; however, an optimal treatment for abdominal symptoms that occur during OIT has not been established.

In the present study, we described the cases of 5 children who successfully continued OIT after the introduction of LTRAs.

A retrospective survey of the medical records of 63 children who underwent OIT between 2010 and 2011 at Kansai Medical University was performed. Children who received LTRAs from the start of OIT were excluded.
from the study. We identified the medical records of 5 children with food allergies [3 allergic to hen’s egg (HE), 1 to wheat, and one to cow’s milk (CM)] who were started on LTRAs during OIT, these patients were enrolled in the study.

The OIT was performed according to Itoh’s protocol [5]. Before OIT, a double-blind, placebo control food challenge was performed, and all five participants had positive challenges. All five were hospitalized during the rush phase of OIT as per protocol. The target doses of HE, wheat (noodles), and CM in the rush phase were 50 g, 200 g, and 200 ml, respectively. Ingestion of the target dose was continued at home every day to maintain the effect of OIT for at least 6–12 months in the maintenance phase.

All study protocols were approved by the Institutional Ethics Committee of Kansai Medical University.

Data for each of the five participants, who were each started LTRAs during OIT, are summarized in Table 1. All five developed severe abdominal pain and were unable to continue OIT before receiving LTRAs. The clinical course of each participant is summarized below.

Case 1: HE allergic
OIT was initiated at 0.001 g of cooked egg. Repeated, severe abdominal symptoms frequently are redundant during the rush phase; therefore, the dose of egg could not be increased. It remained 1.5 g at 27 days after initiation of OIT. After administration of LTRAs, severe abdominal symptoms no longer occurred with any frequency, and the target dose was achieved after 22 days.

Case 2: HE allergic
OIT was initiated at 1.0 g of cooked egg. The dose increased to 8.6 g with no severe adverse reactions for five days. However, for the following three days, OIT could not proceed due to repeated, severe abdominal symptoms. After administration of LTRAs, abdominal symptoms resolved completely, and the target dose could be tolerated six days later.

Case 3: HE allergic
OIT was initiated at 0.001 g of cooked egg. The dose increased to 2.6 g with no severe adverse allergic reaction for 15 days. However, for the following five days, OIT could not proceed due to repeated, severe abdominal symptoms. Although the patient subsequently experienced mild abdominal symptoms once, the target dose was well-tolerated 5 days after the administration of LTRAs.

Case 4: wheat allergic
OIT was initiated at 0.6 g of udon noodle. The dose increased to 3.1 g with no severe adverse allergic reaction for four days. However, for the following three days, OIT could not proceed due to repeated, severe abdominal symptoms. Although the patient subsequently experienced mild abdominal symptoms twice, the target dose was well-tolerated 10 days after the administration of LTRAs.

Case 5: CM allergic
During the rush phase of OIT, the participant experienced no severe side effects and the target dose was ultimately reached for 11 days. However, 49 days after the end of the rush phase, the dose was decreased to 10 ml due to intractable abdominal pain and diarrhea. These symptoms resolved completely after LTRAs administration, and, by gradually increasing the dose by 1 ml each day, the target dose was tolerated for seven months, even though intractable abdominal pain was experienced three times and diarrhea twice during this time.

| Case | 1 | 2 | 3 | 4 | 5 |
|------|---|---|---|---|---|
| Age (years) | 11 | 8 | 12 | 8 | 7 |
| Sex (male/female) | M | M | M | M | F |
| Food | Egg | Egg | Egg | Wheat | Cow’s milk |
| Study phase at the start of LTRAs administration | Rush | Rush | Rush | Rush | M. P. |
| Frequencies/dose of A5 before administration of LTRAs | 0.47 | 0.57 | 0.29 | 0.50 | 0.93 |
| Duration (days) of persistent A5 before administration of LTRAs | 6 | 4 | 5 | 4 | 7 |
| Specific IgE level (U/ml) before administration of LTRAs | 25.1 | 12.7 | 9.61 | 78.1 | 0.90 |
| Specific IgE level (U/ml) after administration of LTRAs | 19.7 | 12.0 | 7.86 | 52.2 | 0.73 |
| Treatment period (months) of LTRAs | 5 | 6 | 2 | 5 | 5 |

LTRAs: leukotriene receptor antagonists.
M. P.: maintenance phase.
A5: abdominal symptoms.
All participants were able to continue the maintenance dose without severe allergic abdominal symptoms after the introduction of LTRAs. Finally, more than one year after the start of OIT, they were able to maintain the target dose of each food without the need for LTRAs.

In the OIT literature, food-induced allergic symptoms are reportedly seen in 50-60% of cases [6,7]. Longo et al. [8] also reported that 23 of 30 children with CM allergy in their OIT group experienced food-induced allergic abdominal symptoms.

LTRAs are used to treat the abdominal symptoms of EG. Although the occurrence of EG is generally very low, it frequently develops during OIT. However, to the best of our knowledge, the effectiveness of LTRAs for food-induced allergic abdominal symptoms has yet to be reported. In the present study, we focused on the efficacy of LTRAs for severe food-induced allergic abdominal symptoms during OIT, which was often interrupted because of these symptoms. All participants were given LTRAs, and OIT was subsequently tolerated; all achieved the target dose and maintained OIT. This result suggests that LTRA controls food-induced severe allergic abdominal symptoms. The mechanism of LTRA efficacy during OIT may be explained by the inhibition of eosinophilic activation [9] and degranulation of mast cells, both of which are triggered by leukotriene [10].

Four studies have reported the occurrence of eosinophilic esophagitis (EE) during OIT [11-14]. However only one study showed that the causative food directly induces EE during OIT for the children with CM allergy, and the frequency of EE during OIT is 2.72% (3 out of 110 patients) [14]. In the present study, EE was not observed in the 63 patients [24 allergic to hen’s egg (HE), 12 to wheat, and 27 to cow’s milk (CM)] receiving OIT; the patients did not show typical symptoms of EE such as general weakness, low physical activity, sleep disturbance, and slow growth, retrosternal pain, dysphagia, and abdominal pain immediately after the ingestion of causative food. And also 10 out of the 63 patients had already received LTRA because of the treatment for persistent asthma. The difference may be because of the preventive effect of LTRAs in the development of EE or different causative food; thus, LTRAs are effective in the treatment of EE [15].

Although a larger, double-blind, placebo controlled study is needed to confirm the current results, we suggest that LTRA may prove to be therapeutically efficacious for treatment of food-induced severe allergic abdominal symptoms during OIT.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MT and ST conceived the study, designed the study and wrote the paper. KS and YH participated in its design and writing. KS helped to edit the manuscript. All authors read and approved the final manuscript.

Acknowledgment
The Mami Mizutani Foundation supported this study.

Received: 5 October 2013 Accepted: 14 January 2014
Published: 17 January 2014

References
1. Khonaty E, Umetsu DT: Oral immunotherapy for food allergy: towards a new horizon. Allergy Asthma Immunol Res 2013, 5:3-15.
2. Khan S, Orenstein SR: Eosinophilic gastroenteritis: epidemiology, diagnosis and management. Paediatr Drugs 2002, 4:563-570.
3. Duroudier NP, Tulah AS, Sayers I: Leukotriene pathway genetics and pharmacogenetics in allergy. Allergy 2009, 64:823-839.
4. Morikawa A, Nishima S: Japanese society of pediatric allergy and clinical immunology. New Japanese pediatric guidelines for the treatment and management of bronchial asthma. Pediatr Int 2007, 49:1023-1031.
5. Patriarca G, Nucera E, Roncallo C, Pollastrini E, Bartolozzi F, De Pasquale F, De Pasquale T, Buononno A, Gasbarrini G, Di Campi C, Schiavino D: Oral desensitizing treatment in food allergy: clinical and immunological results. Alliment Pharmacol Ther 2003, 17:459-465.
6. Itch N, Tagaki Y, Kurihara K: Rush specific oral tolerance induction in school-age children with severe egg allergy: one year follow up. Allergol Int 2010, 59:63-51.
7. Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG: A protocol for oral desensitization in children with IgE-mediated cow’s milk allergy. Allergy 2004, 59:980–987.
8. Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L, Ventura A: Specific oral tolerance induction in children with very severe cow’s milk-induced reactions. J Allergy Clin Immunol 2008, 121:343–347.
9. Wan D, Liu X, Li G: The effects of montelukast on eosinophilic gastroenteritis in a mouse model. Immunopharmacol Immunotoxicol 2013, 35:292–295.
10. Cikler E, Enoy Y, Cetinel S, Ercan F: The leukotriene D4 receptor antagonist, montelukast, inhibits mast cell degranulation in the dermis induced by water avoidance stress. Acta Histochem 2009, 111:112–118.
11. Nariety SD, Skripak JM, Steele P, Hamilton RG, Matsui EC, Burks AW: Wood RA Open-label maintenance after milk oral immunotherapy for IgE-mediated cow’s milk allergy. J Allergy Clin Immunol 2009, 124:610–612.
12. Kim JS, Nowak-Wegrzyn A, Sicherer S, Noone S, Moshier EL, Sampson HA: Dietary baked milk accelerates the resolution of cow’s milk allergy in children. J Allergy Clin Immunol 2011, 128:125–131.
13. Hofmann AM, Scullock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, Kamilaris J, Burks AW: Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol 2009, 124:286–291 e1-6.
14. Sanchez-Garcia S, Rodriguez Del Rio P, Escudero C, Martinez-Gomez M, Ibasco MD: Possible eosinophilic esophagitis induced by milk oral immunotherapy. J Allergy Clin Immunol 2012, 129:1155–7.
15. Atwood SEA, Lewis CJ, Bronder CS, Morris CD, Armstrong GR, Whittam J: Eosinophilic oesophagitis: a novel treatment using Montelukast. Gut 2003, 52:181–185.

doi:10.1186/1710-1492-10-3
Cite this article as: Takahashi et al.: New efficacy of LTRAs (montelukast sodium): it possibly prevents food-induced abdominal symptoms during oral immunotherapy. Allergy, Asthma & Clinical Immunology 2014 10:3.